Spruce Biosciences, Inc. announced its financial results for the full year ended December 31, 2023 and provided updates on its clinical trials of tildacerfont in adult and pediatric classic CAH.
AI Assistant
SPRUCE BIOSCIENCES INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.